# Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

Study · id `cardio:ct-nct01708902` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01708902](<https://clinicaltrials.gov/study/NCT01708902>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01708902

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 876 participants.

## Technical summary

Registry record NCT01708902. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-04-24.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 876 participants (enrolled count; ClinicalTrials.gov record NCT01708902, source copy `cardio:ctgov-nct01708902-2015-04-24`, retrieved 2026-10-26)
- Start date: 2012-10 (registry gives no type) (ClinicalTrials.gov record NCT01708902, source copy `cardio:ctgov-nct01708902-2015-04-24`, retrieved 2026-10-26)
- Primary completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01708902, source copy `cardio:ctgov-nct01708902-2015-04-24`, retrieved 2026-10-26)
- Completion: 2014-04 (actual) (ClinicalTrials.gov record NCT01708902, source copy `cardio:ctgov-nct01708902-2015-04-24`, retrieved 2026-10-26)
- Results first posted: 2015-04-24 (ClinicalTrials.gov record NCT01708902, source copy `cardio:ctgov-nct01708902-2015-04-24`, retrieved 2026-10-26)
- Countries: China; Malaysia; Philippines; Vietnam (ClinicalTrials.gov record NCT01708902, source copy `cardio:ctgov-nct01708902-2015-04-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01708902-2015-04-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): linagliptin2.5mg/metformin1000mg
- Intervention (Drug): linagliptin2.5mg/metformin1000mg
- Intervention (Drug): linagliptin 5mg
- Intervention (Drug): Metformin 500mg
- Intervention (Drug): linagliptin2.5mg/metformin500mg
- Intervention (Drug): linagliptin2.5mg/metformin500mg
- Intervention (Drug): linagliptin 5mg
- Intervention (Drug): Metformin 1000mg
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 784c9d700bac5c697e664ef228dd31f19e4f3883ff452843eab92bbe4925457d
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
